Sandip P. Patel, MD - Medical Oncology ...

Dr. Sandip Patel, MD

Claim this profile

UC San Diego Moores Cancer Center

Expert in Lung Cancer
Expert in Cancer
25 reported clinical trials
46 drugs studied

Area of expertise

1

Lung Cancer

Global Leader

Sandip Patel, MD has run 13 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
EGFR negative
2

Cancer

Global Leader

Sandip Patel, MD has run 13 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HLA-A positive

Affiliated Hospitals

Image of trial facility.

UC San Diego Moores Cancer Center

Image of trial facility.

University Of California San Diego

Clinical Trials Sandip Patel, MD is currently running

Image of trial facility.

SW-682

for Solid Tumors

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.

Recruiting

1 award

Phase 1

6 criteria

Image of trial facility.

CAR T-Cell Preparation

for Cancer

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.

Recruiting

1 award

N/A

3 criteria

More about Sandip Patel, MD

Clinical Trial Related

3 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 7 Active Clinical Trials

Treatments Sandip Patel, MD has experience with

  • Nivolumab
  • Pembrolizumab
  • Ipilimumab
  • AZD2936
  • Carboplatin
  • Cisplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Sandip Patel, MD specialize in?

Is Sandip Patel, MD currently recruiting for clinical trials?

Are there any treatments that Sandip Patel, MD has studied deeply?

What is the best way to schedule an appointment with Sandip Patel, MD?

What is the office address of Sandip Patel, MD?

Is there any support for travel costs?